Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds - 2Audits of 6 American Busssiness Class Flights
- 3From Lounge chair to Money: Online Positions That Will Change Your Profession
- 4Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\
- 5Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces
- Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- The most effective method to Pick the Right Material Organization: Fundamental Tips
- Manual for Notorious Fragrances: Immortal Aromas
- We may have one thing in common with jellyfish, new research finds
- Must-Sit in front of the Programs from Europe and the US
- Astrophotographer captures rare footage of the Hubble Telescope crossing the sun (video)
- Find the Advantages of Deep rooted Getting the hang of: Extending Information and Self-awareness
- Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- Vote in favor of the pasta that makes good dieting pleasant!
